Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor

被引：1

作者：

Hagihara, Shuichi ^{[1
]}

Ishizawa, Kouhei ^{[1
]}

Soga, Kana ^{[1
]}

Honjo, Takashi ^{[1
]}

Takai, Shigeki ^{[1
]}

Kawano, Yuko ^{[1
]}

Kikuchi, Manami ^{[1
]}

Nishidate, Akiko ^{[1
]}

Matsumoto, Fumi ^{[1
]}

Murase, Mikako ^{[1
]}

Hashimoto, Naohiro ^{[1
]}

Sasaki, Chiduko ^{[1
]}

Miyaguchi, Ikuko ^{[1
]}

Okada, Okimasa ^{[1
]}

Akashi, Tomoya ^{[1
]}

Nakayama, Shinji ^{[1
]}

Ogasawara, Yuko ^{[1
]}

Endo, Junichi ^{[1
]}

机构：

[1] Mitsubishi Tanabe Pharm Corp, Sohyaku Innovat Res Div, 1000 Kamoshida Cho,Aoba Ku, Yokohama 2270033, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2024年 / 109卷

关键词：

BET family; BD1; selectivity; X-ray crystallography; Inflammation; Pyrazolopyridone; PROTEIN; CHROMATIN; BRD4;

D O I：

10.1016/j.bmcl.2024.129849

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Clinical studies have shown that inhibitors of bromodomain and extra-terminal domain (BET) proteins, particularly BRD4, have antitumor activity and efficacy. The BET protein has two domains, BD1 and BD2, and we previously focused on BD1 and reported orally bioavailable BD1-selective inhibitors. In this study, we obtained a BD1 inhibitor, a more potent and highly selective pyrazolopyridone derivative 13a, and confirmed its in vivo efficacy.

引用

页数：6

共 50 条

[31] Phase I dose-finding study of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (pts) with advanced malignancies
Bechter, O.
Aftimos, P.
Awada, A.
Rottey, S.
Machiels, J. P.
Dumez, H.
Jungels, C.
Costermans, J.
Huyvaert, N.
Zografos, E.
Meeus, M. A.
Musa, H.
Burkard, U.
Zhao, Y.
Schoffski, P.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E16 - E16
[32] Rational therapeutic combination of Bromodomain and Extra-Terminal domain (BET) inhibitor and Fibroblast Growth Factor Receptor (FGFR) inhibitor for treatment of invasive lobular carcinoma
Gao, Binbin
Ward, Elspeth
Blumel, Anna
Conroy, Emer
Moore, Rachel
Cremin, Grainne
Bleach, Rachel
Haley, Kathryn
Ni Chonghaile, Triona
Lindner, Andreas
Lindner, Andreas
Prehn, Jochen
Zhang, Yi
Cruz, Idalia
Hilakivi-Clarke, Leena
Sflomos, Georgios
Brisken, Cathrin
Gallagher, William
O'Connor, Darran
CANCER RESEARCH, 2024, 84 (09)
[33] Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design
Gavai, Ashvinikumar, V
Norris, Derek
Delucca, George
Tortolani, David
Tokarski, John S.
Dodd, Dharmpal
O'Malley, Daniel
Zhao, Yufen
Quesnelle, Claude
Gill, Patrice
Vaccaro, Wayne
Tram Huynh
Ahuja, Vijay
Han, Wen-Ching
Mussari, Christopher
Harikrishnan, Lalgudi
Kamau, Muthoni
Poss, Michael
Sheriff, Steven
Yan, Chunhong
Marsilio, Frank
Menard, Krista
Wen, Mei-Li
Rampulla, Richard
Wu, Dauh-Rurng
Li, Jianqing
Zhang, Huiping
Li, Peng
Sun, Dawn
Yip, Henry
Traeger, Sarah C.
Zhang, Yingru
Mathur, Arvind
Zhang, Haiying
Huang, Christine
Yang, Zheng
Ranasinghe, Asoka
Everlof, Gerry
Raghavan, Nirmala
Tye, Ching Kim
Wee, Susan
Hunt, John T.
Vite, Gregory
Westhouse, Richard
Lee, Francis Y.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14247 - 14265
[34] Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins
Harrison, Lee A.
Atkinson, Stephen J.
Bassil, Anna
Chung, Chun-wa
Grandi, Paola
Gray, James R. J.
Levernier, Etienne
Lewis, Antonia
Lugo, David
Messenger, Cassie
Michon, Anne-Marie
Mitchell, Darren J.
Preston, Alex
Prinjha, Rab K.
Rioja, Inmaculada
Seal, Jonathan T.
Taylor, Simon
Wall, Ian D.
Watson, Robert J.
Woolven, James M.
Demont, Emmanuel H.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 10742 - 10771
[35] Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Seal, Jonathan T.
Atkinson, Stephen J.
Bamborough, Paul
Bassil, Anna
Chung, Chun-Wa
Foley, James
Gordon, Laurie
Grandi, Paola
Gray, James R. J.
Harrison, Lee A.
Kruger, Ryan G.
Matteo, Jeanne J.
McCabe, Michael T.
Messenger, Cassie
Mitchell, Darren
Phillipou, Alex
Preston, Alex
Prinjha, Rab K.
Rianjongdee, Francesco
Rioja, Inmaculada
Taylor, Simon
Wall, Ian D.
Watson, Robert J.
Woolven, James M.
Wyce, Anastasia
Zhang, Xi-Ping
Demont, Emmanuel H.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 10772 - 10805
[36] Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model
Sato, Masanori
Kondo, Takekazu
Kohno, Yasushi
Seto, Shigeki
BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 34
[37] APABETALONE, A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, REDUCES SERUM FGF23 IN CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE PATIENTS
Kalantar-Zadeh, Kamyar
Zoccali, Carmine
Beddhu, Srinivasan
Brandenburg, Vincent
Haarhaus, Mathias
Tonelli, Marcello
Khan, Aziz
Halliday, Christopher
Lebioda, Ken
Johansson, Jan O.
Sweeney, Michael
Wong, Norman C. W.
Kulikowski, Ewelina
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
[38] First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies
Postel-Vinay, S.
Herbschleb, K.
Massard, C.
Woodcock, V.
Ocker, M.
Wilkinson, G.
Walter, A.
Ewerton, F.
Poelman, M.
Middleton, M.
Soria, J. C.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S7 - S8
[39] Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor
Sperandio, David
Aktoudianakis, Vangelis
Babaoglu, Kerim
Chen, Xiaowu
Elbel, Kristyna
Chin, Gregory
Corkey, Britton
Du, Jinfa
Jiang, Bob
Kobayashi, Tetsuya
Mackman, Richard
Martinez, Ruben
Yang, Hai
Zablocki, Jeff
Kusam, Saritha
Jordan, Kim
Webb, Heather
Bates, Jamie G.
Lad, Latesh
Mish, Michael
Niedziela-Majka, Anita
Metobo, Sammy
Sapre, Annapurna
Hung, Magdeleine
Jin, Debi
Fung, Wanchi
Kan, Elaine
Eisenberg, Gene
Larson, Nate
Newby, Zachary E. R.
Lansdon, Eric
Tay, Chin
Neve, Richard M.
Shevick, Sophia L.
Breckenridge, David G.
BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (03) : 457 - 469
[40] APABETALONE (RVX-208), A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, DECREASES ABUNDANCE AND ACTIVITY OF COMPLEMENT PROTEINS IN VITRO, IN MICE AND IN CLINICAL STUDIES
Wong, Norman Cw
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Wasiak, Sylwia
Gilham, Dean
Halliday, Christopher
Sweeney, Mike
Johansson, Jan
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 109 - 109

← 1 2 3 4 5 →